A Phase I/II Study of CX-4945 in Combination With Gemcitabine and Cisplatin in the Frontline Treatment of Patients With Cholangiocarcinoma
Phase of Trial: Phase I/II
Latest Information Update: 26 Oct 2017
At a glance
- Drugs Silmitasertib (Primary) ; Cisplatin; Gemcitabine
- Indications Cholangiocarcinoma
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Senhwa Biosciences
- 19 Oct 2017 Planned number of patients changed from 100 to 209.
- 19 Oct 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2018.
- 19 Oct 2017 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2018.